News
SYBE
0.055
NaN%
--
Weekly Report: what happened at SYBE last week (0908-0912)?
Weekly Report · 09/15 10:23
Weekly Report: what happened at SYBE last week (0901-0905)?
Weekly Report · 09/08 10:25
Weekly Report: what happened at SYBE last week (0825-0829)?
Weekly Report · 09/01 10:22
Weekly Report: what happened at SYBE last week (0818-0822)?
Weekly Report · 08/25 10:28
Weekly Report: what happened at SYBE last week (0811-0815)?
Weekly Report · 08/18 10:23
Weekly Report: what happened at SYBE last week (0804-0808)?
Weekly Report · 08/11 10:27
Weekly Report: what happened at SYBE last week (0728-0801)?
Weekly Report · 08/04 10:30
Weekly Report: what happened at SYBE last week (0721-0725)?
Weekly Report · 07/28 10:30
Weekly Report: what happened at SYBE last week (0714-0718)?
Weekly Report · 07/21 10:24
Weekly Report: what happened at SYBE last week (0707-0711)?
Weekly Report · 07/14 10:29
Weekly Report: what happened at SYBE last week (0630-0704)?
Weekly Report · 07/07 10:24
Weekly Report: what happened at SYBE last week (0623-0627)?
Weekly Report · 06/30 10:28
Weekly Report: what happened at SYBE last week (0616-0620)?
Weekly Report · 06/23 10:24
Weekly Report: what happened at SYBE last week (0609-0613)?
Weekly Report · 06/16 10:28
Weekly Report: what happened at SYBE last week (0602-0606)?
Weekly Report · 06/09 10:29
Weekly Report: what happened at SYBE last week (0526-0530)?
Weekly Report · 06/02 10:34
Weekly Report: what happened at SYBE last week (0519-0523)?
Weekly Report · 05/26 10:34
Weekly Report: what happened at SYBE last week (0512-0516)?
Weekly Report · 05/19 10:27
Weekly Report: what happened at SYBE last week (0505-0509)?
Weekly Report · 05/12 10:28
Weekly Report: what happened at SYBE last week (0428-0502)?
Weekly Report · 05/05 10:30
More
Webull provides a variety of real-time SYBE stock news. You can receive the latest news about SYBLEU Inc through multiple platforms. This information may help you make smarter investment decisions.
About SYBE
SYBLEU Inc. is engaged in the acquisition, licensing and development of medical and veterinary applications. The Company is focused on developing therapies for human and animal health, medical devices, and clinical diagnostics. The Company is also developing drugs for treating cancer in companion animals and examining the role of artificial intelligence and machine learning in clinical diagnostics. It is also involved in the development of disposable medical devices. The Company has completed Phase I and or Phase II clinical trials, after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.